ArticleActa physiologica (Oxford, England)2026
Alms1 KO Rat: A New Model of Cardiometabolic Syndrome With Spontaneous Hypertension.
Article in Acta physiologica (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Alms1 KO Rat: A New Model of Cardiometabolic Syndrome With Spontaneous Hypertension.Acta physiologica (Oxford, England) · 2026Article
Corrections and comments
- Update of
Authors and funding
7 authors.
Funding
Abstract
Alström syndrome 1 (ALMS1) is a protein linked to Alström syndrome, a rare genetic disorder characterized by obesity, insulin resistance, hyperinsulinemia, and hypertension. Genetic studies have further associated Alms1 with hypertension in human populations. However, the precise mechanisms by which ALMS1 regulates metabolic and cardiovascular function remain unclear.
aimIn this study, we investigate metabolic and cardiovascular functions regulated by ALMS1.
methodsTo investigate this, we developed and characterized an Alms1 knockout (KO) rat model, which spontaneously develops metabolic syndrome and hypertension.
resultsOur findings reveal that Alms1 KO rats exhibit age-dependent metabolic dysfunction, with hypertension and increased body weight becoming evident by 10-12 weeks of age. Obesity, hyperinsulinemia, and vascular dysfunction emerge later, at 14-16 weeks, suggesting progressive metabolic deterioration. Notably, Alms1 KO rats develop hyperleptinemia as early as 7 weeks, prior to the onset of obesity, implicating ALMS1 in early leptin regulation and metabolic signaling. Moreover, female Alms1 KO rats develop severe metabolic syndrome with hypertension, like males, demonstrating a lack of the typical female cardiovascular protection. Echocardiographic analysis shows progressive cardiac dysfunction, including left ventricular (LV) dilation, increased wall thickness, and impaired contractility. Despite these structural changes, the LV mass/BW ratio remains unchanged, suggesting a shift toward maladaptive eccentric remodeling rather than hypertrophy.
conclusionCollectively, these findings establish the Alms1 KO rat as a robust preclinical model of metabolic syndrome. This model closely mimics human disease and provides a powerful tool for studying the mechanisms of metabolic and cardiovascular dysfunction as well as for testing potential therapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.